Surveillance of Activity of Netilmicin in Comparison with Other Antimicrobials against Russian Ophtalmic Bacterial Isolates

Clinical Microbiology and Antimicrobial Chemotherapy. 2015; 17(3):241-249

​ Maychuk D.Yu., Dekhnich A.V., Sukhorukova M.V.
netilmicin aminoglycosides ophthalmology antimicrobial resistance
Section
Personal Experience
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2015; 17(3):241-249

Objective.

Aim. To evaluate current susceptibility patterns of the potential ocular bacterial pathogens to netilmicin in comparison with other antimicrobials in Russia.

Materials and Methods.

Overall in the study were included 200 S. aureus strains (100 — MRSA), 50 — coagulase-negative staphylococci, 50 — P. aeruginosa, 50 — Acinetobacter spp., and 50 — Enterobacteriaceae strains, isolated from outpatients and inpatients located in 17 cities of different regions of Russia during 2010–2014. All strains were identified to the species level using MALDI-TOF mass-spectrometry. Minimal inhibitory concentrations (MICs) of netilmicin and other antimicrobials were determined by serial dilution method and interpreted according EUCAST criteria (v.4.1).

Results.

Activity of netilmicin against methicillin-susceptible S. aureus strains (98% of isolates were susceptible to netilmicin) according to MIC50/90 values was superior compare to other aminoglycosides (gentamicin, tobramycin) and lower only if compared with respiratory quinolones and fusidic acid. In spite the fact that all MRSA isolates were formally resistant to netilmicin (as well as to gentamicin and tobramycin), according to MIC50/90 values and MIC distributions netilmicin was superior to majority of antimicrobials tested with exception of tigecycline, fusidic acid and co-trimoxazole. Against coagulase-negative staphylococci netilmicin (96% isolates susceptible) was the most in vitro active among all antimicrobials tested. According to MIC50/90 values, in vitro activity of netilmicin (46% isolates susceptible) against Enterobacteriaceae was comparable with the activity of other aminoglycosides, quinolones, cephalosporins, co-trimoxazole, and inhibitor-protected aminopenicillins. In vitro activity of netilmicin against P. aeruginosa and Acinetobacter spp. (50% and 76% susceptible isolates, respectively) was higher compare with other aminoglycosides (amikacin, gentamicin, tobramycin), and with other antimicrobials tested except colistin.

Conclusions.

Netilmicin might be considered as an option for the topical treatment of bacterial eye infections, especially nosocomial, as well as for topical prophylaxis in eye surgery.

Maychuk D.Yu.

FGAU MNTK «Eye Microsurgery» Named Under S.N. Fedorov, Moscow, Russia

Andrey V. Dekhnich

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Marina V. Sukhorukova

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Leeming J.P. Treatment of ocular infections with topical antibacterials. Clin Pharmacokinet 1999; 37:351-60.
  • 2. Thanathanee O., O’Brien T.P. Conjunctivitis: systematic approach to diagnosis and therapy. Curr Infect Dis Rep 2011; 13:141-8.
  • 3. Kowalski R.P., Dhaliwal D.K. Expert Re Anti Infect Ther 2005; 3:131-9.
  • 4. Chalita M.R., Hofling-Lima A.L., Paranhos A., Schor P., Belfort R. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol 2004; 137:43-51.
  • 5. Haas W., Pillar C.M., Torres M., Morris T.W., Sahm D.F. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol 2011; 152:567-74 e563.
  • 6. Morrissey I., Burnett R., Viljoen L., Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002. J Infect 2004; 49:109-14.
  • 7. Kowalski R.P., Yates K.A., Romanowski E.G., Karenchak L.M., Mah F.S., Gordon Y.J. An ophthalmologist’s guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology 2005; 112(11):1987.
  • 8. Kowalski R.P., Romanowski E.G., Mah F.S., Sasaki H., Fukuda M., Gordon Y.J. A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinoloneresistant Staphylococcus aureus rabbit model. Jpn. J. Ophthalmol. 52(3), 211-16 (2008).
  • 9. Kowalski RP, Romanowski EG, Mah FS, Shanks RM, Gordon YJ. Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models. Acta Ophthalmol. 88(4), e120-e125 (2010).
  • 10. ISO 20776-1:2006 «Clinical laboratory testing and in vitro diagnostic test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices» - Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases.
  • 11. Национальный Стандарт ГОСТ Р ИСО 20776-1-2010 Клинические лабораторные исследования и диагностические тест-системы in vitro. Исследование чувствительности инфекционных агентов и оценка функциональных характеристик изделий для исследования чувствительности к антимикробным средствам. Часть 1. Референтный метод лабораторного исследования активности антимикробных агентов против быстрорастущих аэробных бактерий, вызывающих инфекционные болезни.
  • 12. European Committee on Antimicrobial Susceptibility testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Ver. 4.02014 (http://www.eucast.org/clinical_breakpoints/).
  • 13. Haas W., Pillar C.M., Torres M., Morris T.W., Sahm D.F. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol 2011; 152:567-74.
  • 14. Blanco A.R., Sudano R.A, Spoto C.G., Papa V. Susceptibility of methicillin-resistant Staphylococci clinical isolates to netilmicin and other antibiotics commonly used in ophthalmic therapy. Curr Eye Res 2013; 38:811-6.
  • 15. Papa V., Aragona P.; Scuderi A., et al. Treatment of Acute Bacterial Conjunctivitis With Topical Netilmicin. Cornea 2002; 21:43-7.
  • 16. Aslan O., Teberik K., Yucel M., Gur N., Karakoc A.E. Effect of topical netilmicin on the reduction of bacterial flora on the human conjunctiva. Eur J Ophthalmol 2008; 18:512-6.
  • 17. Faraldi F., Papa V., Rasà D., Santoro D., Russo S. Netilmicin/dexamethasone fixed combination in the treatment of conjunctival inflammation. Clin Ophthalmol 2013; 7:1239-44.
  • 18. Milazzo G., Papa V., Carstocea B., e.a. Topical netilmicin compared with tobramycin in the treatment of external ocular infection. Int J Clin Pharmacol Ther 1999; 37:243-8.
  • 19. Scuderi A.C., De Lazzari A., Miano F., Zola P. Residence time of netilmicin in tears. Cornea 2002; 21:48-50.
  • 20. Leonardi A., Papa V., Fregona I., et al. In vitro effects of fluoroquinolone and aminoglycoside antibiotics on human keratocytes. Cornea 2006; 25:85-90.
  • 21. Marino C., Paladino G.M., Scuderi A.C., et al. In vivo toxicity of netilmicin and ofloxacin on intact and mechanically damaged eyes of rabbit. Cornea 2005; 24:710-6.
  • 22. Sosa A.B., Epstein S.P., Asbell P.A. Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells. Cornea 2008; 27:930-4.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared